Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
NCT04858256Phase 2Recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Mar 2023
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pacritinib in T cell lymphoproliferative neoplasm, peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), sponsored by University of Michigan Rogel Cancer Center. Started Mar 2023; status: recruiting.
02
Drugs
pacritinib
03
Conditions
T cell lymphoproliferative neoplasmperipheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT04858256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04858256.